Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001213900-14-006190
Filing Date
2014-08-21
Accepted
2014-08-21 17:17:10
Documents
15

Document Format Files

Seq Description Document Type Size
1 PROSPECTUS f424b30814_dandrit.htm 424B3 2615276
2 img001_v1.jpg GRAPHIC 4919
3 sunrise.jpg GRAPHIC 10685
4 benchmark.jpg GRAPHIC 9058
5 img002_v1.jpg GRAPHIC 6426
6 img003_v1.jpg GRAPHIC 29567
7 img004_v1.jpg GRAPHIC 28027
8 img012.jpg GRAPHIC 34408
9 img005_v1.jpg GRAPHIC 7409
10 img006_v1.jpg GRAPHIC 33049
11 img007_v1.jpg GRAPHIC 50321
12 img008_v1.jpg GRAPHIC 55507
13 img008a_v1.jpg GRAPHIC 15416
14 img009_v1.jpg GRAPHIC 6099
15 img.jpg GRAPHIC 27816
  Complete submission text file 0001213900-14-006190.txt   3057171
Mailing Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7
Business Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7 45 39179840
DanDrit Biotech USA, Inc. (Filer) CIK: 0001527728 (see all company filings)

EIN.: 452259340 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-193965 | Film No.: 141058369
SIC: 2834 Pharmaceutical Preparations